IL69930A - Oral mopidamol preparations and their production - Google Patents

Oral mopidamol preparations and their production

Info

Publication number
IL69930A
IL69930A IL69930A IL6993083A IL69930A IL 69930 A IL69930 A IL 69930A IL 69930 A IL69930 A IL 69930A IL 6993083 A IL6993083 A IL 6993083A IL 69930 A IL69930 A IL 69930A
Authority
IL
Israel
Prior art keywords
acid
mopidamol
addition salt
preparations
oral
Prior art date
Application number
IL69930A
Other languages
English (en)
Other versions
IL69930A0 (en
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of IL69930A0 publication Critical patent/IL69930A0/xx
Publication of IL69930A publication Critical patent/IL69930A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL69930A 1982-10-09 1983-10-07 Oral mopidamol preparations and their production IL69930A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823237575 DE3237575A1 (de) 1982-10-09 1982-10-09 Neue orale mopidamolformen

Publications (2)

Publication Number Publication Date
IL69930A0 IL69930A0 (en) 1984-01-31
IL69930A true IL69930A (en) 1986-08-31

Family

ID=6175408

Family Applications (1)

Application Number Title Priority Date Filing Date
IL69930A IL69930A (en) 1982-10-09 1983-10-07 Oral mopidamol preparations and their production

Country Status (18)

Country Link
US (2) US4596705A (ja)
EP (1) EP0108898B1 (ja)
JP (1) JPH07558B2 (ja)
AT (1) ATE21481T1 (ja)
AU (1) AU560251B2 (ja)
CA (1) CA1228546A (ja)
DE (2) DE3237575A1 (ja)
DK (1) DK158541C (ja)
ES (1) ES526331A0 (ja)
FI (1) FI79650C (ja)
GB (1) GB2128088B (ja)
GR (1) GR79015B (ja)
IE (1) IE56058B1 (ja)
IL (1) IL69930A (ja)
NO (1) NO833638L (ja)
NZ (1) NZ205894A (ja)
PT (1) PT77467B (ja)
ZA (1) ZA837499B (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8414220D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
US5364646A (en) * 1990-01-10 1994-11-15 Dr. Karl Thomae Gmbh Oral pharmaceutical forms of pimobendan
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
US5156845A (en) * 1990-05-04 1992-10-20 Colgate-Palmolive Company Dry mouth lozenge
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
WO1992020326A1 (en) * 1991-05-20 1992-11-26 Marion Laboratories, Inc. Multi-layered controlled release formulation
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
CN100341483C (zh) * 2000-02-28 2007-10-10 维克丘拉有限公司 口服药物输递中或涉及口服药物输递的改进
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1594503A2 (en) * 2003-02-07 2005-11-16 Boehringer Ingelheim International GmbH Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders
AU2004231306A1 (en) 2003-04-24 2004-11-04 Boehringer Ingelheim International Gmbh Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors
US7410978B2 (en) * 2003-11-04 2008-08-12 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
AU2004289222B2 (en) * 2003-11-04 2010-01-21 Supernus Pharmaceuticals Inc. Compositions of quaternary ammonium containing bioavailability enhancers
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
EP1863460B1 (en) 2005-03-22 2013-01-16 Losan Pharma GmbH Solubilized ibuprofen
EP1915137B8 (de) * 2005-08-10 2013-09-11 ADD Advanced Drug Delivery Technologies, Ltd. Orales präparat mit kontrollierter freisetzung
BRPI0707324A2 (pt) * 2006-01-27 2011-05-03 Eurand Inc sistemas de fornecimento de fármaco compreendendo agente de bloqueio de serotonina 5-ht3 seletivo fracamente básico e ácidos orgánicos
CN101410093A (zh) * 2006-01-27 2009-04-15 欧兰德股份有限公司 包含弱碱性药物和有机酸的药物递送系统
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
EP2702986A1 (en) 2008-11-25 2014-03-05 Boehringer Ingelheim Vetmedica GmbH Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
HUE060093T2 (hu) 2012-03-15 2023-01-28 Boehringer Ingelheim Vetmedica Gmbh Gyógyszerészeti tablettakészítmény az állatgyógyászati ágazat számára, eljárás annak elõállítására és annak alkalmazása
PL2898886T3 (pl) 2012-09-19 2017-06-30 Taiho Pharmaceutical Co., Ltd. Kompozycja farmaceutyczna do podawania doustnego z polepszoną elucją i/lub wchłanianiem
ES2860526T3 (es) 2013-07-19 2021-10-05 Boehringer Ingelheim Vetmedica Gmbh Derivados de ciclodextrina eterificada conservados que contienen una composición farmacéutica acuosa líquida
ES2593210T3 (es) 2013-12-04 2016-12-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmacéuticas mejoradas de pimobendán
JP6525897B2 (ja) * 2016-01-21 2019-06-05 日清オイリオグループ株式会社 タブレットの硬度調整剤
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN109942445A (zh) * 2019-02-26 2019-06-28 山东瑞弘生物科技有限公司 甜菜碱盐酸盐合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3322755A (en) * 1964-03-10 1967-05-30 Boehringer Sohn Ingelheim Basic-substituted 1, 2, 3, 4-tetrahydropyrimido [5, 4-d]-pyrimidines
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
EP0019586A1 (de) * 1979-05-11 1980-11-26 Ciba-Geigy Ag Neue antithrombotische Kombinationspräparate
DE2931573A1 (de) * 1979-08-03 1981-02-26 Thomae Gmbh Dr K Mittel zur bekaempfung des wachstums von krebszellen und dessen herstellung
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen

Also Published As

Publication number Publication date
FI79650C (fi) 1990-02-12
JPH07558B2 (ja) 1995-01-11
EP0108898B1 (de) 1986-08-20
JPS5989615A (ja) 1984-05-23
NZ205894A (en) 1986-08-08
PT77467A (de) 1983-11-01
DK158541C (da) 1990-11-05
US4596705A (en) 1986-06-24
DK460683D0 (da) 1983-10-06
IE832358L (en) 1984-04-09
IL69930A0 (en) 1984-01-31
US4650664A (en) 1987-03-17
DE3237575A1 (de) 1984-04-12
FI833605A0 (fi) 1983-10-05
ZA837499B (en) 1985-06-26
DK158541B (da) 1990-06-05
AU560251B2 (en) 1987-04-02
DE3365465D1 (en) 1986-09-25
ATE21481T1 (de) 1986-09-15
PT77467B (de) 1986-05-07
FI833605A (fi) 1984-04-10
NO833638L (no) 1984-04-10
GB8326877D0 (en) 1983-11-09
CA1228546A (en) 1987-10-27
DK460683A (da) 1984-04-10
ES8500743A1 (es) 1984-11-01
ES526331A0 (es) 1984-11-01
GR79015B (ja) 1984-10-02
IE56058B1 (en) 1991-04-10
AU1998583A (en) 1984-04-12
FI79650B (fi) 1989-10-31
EP0108898A1 (de) 1984-05-23
GB2128088A (en) 1984-04-26
GB2128088B (en) 1986-04-30

Similar Documents

Publication Publication Date Title
IL69930A0 (en) Oral mopidamol preparations and their production
ES8304797A1 (es) "procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas".
EP0682526A4 (en) LENGTH ADMINISTRATION OF SCR1 AND OTHER COMPLEMENT INHIBITORS.
JPS6485984A (en) Methylenephosphonoalkylphosphinates, medicinal composition and therapy for abnormal calcium and phosphate metabolism
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
GR1002091B (en) A process for providing a composition comprising an antidiarrheal and an antiflatulent
ES8609312A1 (es) Procedimiento para la preparacion de silibinina exenta de isosilibina
DE3480053D1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
EP0179808A4 (en) MEDICINAL COMPOSITION SUITABLE FOR TREATING OR PROPHYLAXIS OF HEART DISORDERS.
DE3166111D1 (en) Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes
HUT68876A (en) Pharmaceutical composition for treating tumours, containing creatine phosphate or phospho-enol-pyruvic acid
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
HU9200400D0 (en) Cinurenic acid derivatives, process for producing them and pharmaceutical compositions containing them
GR3024707T3 (en) Digitoxigenin and dihydrodigitoxigenin 3beta-derivatives and pharmaceutical compositions comprising same for the treatment of cardiovascular disorders
DK32893A (da) Geminale cycloalkyldiphosphonsyrer og farmaceutisk acceptable salte heraf samt farmaceutisk sammensaetning omfattende samme
UA43306C2 (uk) Похідні оксаспіро[2,5]октану, що мають ангіогенезну інгібуючу активність, спосіб їх одержання (варіанти)

Legal Events

Date Code Title Description
KB Patent renewed
RH Patent void